On October 9, 2014, Bair, Kenneth W.; Millan, David S.; Martin, Matthew W.; Tebbe, Mark J.; Lu, Wei; Li, Hongbin; Loch, James published a patent.Application of 1417036-28-2 The title of the patent was Preparation of FASN inhibitors useful for treatment of cancer and other diseases. And the patent contained the following:
The invention relates to compounds of formula I as inhibitors of fatty acid synthase (FASN) useful alone or in combination with other drugs for the treatment of disorders such as cancer, autoimmune diseases, inflammatory disorders, and viral infections. I [wherein R1 is a (un)substituted 5- to 6-membered heterocycloalkyl; L is a (un)substituted 5- to 10-membered monocyclic or bicyclic (hetero)alkyl; A and B are independently O or S; Ar is a (un)substituted 3- to 10-membered monocyclic or bicyclic (hetero)aryl or heterocycloalkyl; R2 is H, a (un)substituted (hetero)aryl, or a (un)substituted (hetero)cycloalkyl] and pharmaceutically acceptable salts thereof are claimed and exemplified. Example compound (R)-II was prepared in a multistep process (preparation given). and evaluated for inhibition of cancer cell proliferation using PC3 cells. From the above assay III was determined to exhibit an IC50 value of <0.5 μM. The experimental process involved the reaction of 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(cas: 1417036-28-2).Application of 1417036-28-2
The Article related to fatty acid synthase inhibitor preparation cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Application of 1417036-28-2
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem